Prashant Chaulagain

Internal Medicine Resident @SinaiBmoreIMRes I Blood & Cancer fuel my enthusiasm I Special Interest: Clinical Reasoning & MedEd

[NEJM @NEJM]

Original Article: Survival with Osimertinib plus Chemotherapy in 𝘌𝘎𝘍𝘙-Mutated Advanced NSCLC (FLAURA2 phase 3 trial) https://t.co/r1pDnouYK0

Editorial: Navigating the Evolving Landscape of 𝘌����𝘍𝘙-Mutated NSCLC https://t.co/rGENKRHLfs

#Oncology

[Prashant Chaulagain @Prashant_Med]

@KaiLiangMD @ASCO @AACR @sepideh_gholami @manjuggm @YoussefBouferra @MirLimMD @Guv_onc Congrats @KaiLiangMD

[Prashant Chaulagain @Prashant_Med]

@hira_akhlaq_ @IMG_Oncologists @OncLive @ASCO @SinaiBmoreIMRes Thank you Hira🙏 Grateful for all the support at Sinai.

[Prashant Chaulagain @Prashant_Med]

Excited to share that two of our abstracts have been accepted for poster presentation at the #ASCOQLTY 2025 Symposium!
Looking forward to presenting our research on innovation in medical education and empathy among residents.

@IMG_Oncologists @OncLive @ASCO
#MedEd #empathy

[Prashant Chaulagain @Prashant_Med]

@fumikochino @crisbergerot @IMG_Oncologists @OncLive @ASCO Thank you Dr Chino🙏

[OncoDaily @oncodaily]

@Prashant_Med @IMG_Oncologists @OncLive @ASCO We would like to inform you that your post has been published on OncoDaily. Thank you for sharing.
https://t.co/Olw8GrglU2

[Prashant Chaulagain @Prashant_Med]

Excited to share that I’ve certified and submitted my #HemOncFellowship application!
Grateful for the mentors, patients, and experiences that shaped my journey in hematology & oncology.
Looking forward to the share my story!

@HemOncFellows @hemeoncfellow @IMG_Oncologists

[Prashant Chaulagain @Prashant_Med]

@hira_akhlaq_ @SinaiBmoreIMRes Welcome to @sinai family!!
Thrilled to have you as our chief! Can’t wait to learn from you this year.

[Prashant Chaulagain @Prashant_Med]

@PatrickCMa1 @SinaiBmoreIMRes @rav7ks Thank you Dr. Ma 🙏

[Prashant Chaulagain @Prashant_Med]

Truly humbled and honored to be named ‘Resident of the Year.’ and awarded with “Albert J. Himelfarb Award in Professionalism and Humanism”
Words cannot express my gratitude for the unwavering support of my incredible colleagues and the guidance of my inspiring mentors.

[NEJM @NEJM]

Cancer of unknown primary site encompasses a heterogeneous group of metastatic cancers with an unidentified primary site of origin. Putative site-specific therapy and empirical chemotherapy are acceptable treatment options.

Read the Clinical Practice article “Cancer of Unknown Primary Site” by Kanwal Raghav, MD, from the University of Texas M.D. Anderson Cancer Center (@MDAndersonNews): https://t.co/kyFjYR8B2N

[Vivek Subbiah, MD @VivekSubbiah]

🚨 Wow! #ASCO25 @ASCO was absolutely massive!
10 @NEJM papers published simultaneously 👉 all practice-changing studies ! 🔬✨🧵 See below for these studies 👇@oncoalert

[Prashant Chaulagain @Prashant_Med]

Attending my first ASCO Meeting was more than just a conference—it was an experience, a pulse.
Grateful for all the mentors, peers, and friends I met along the way.
Until next time, ASCO—thank you for the inspiration, the knowledge, and the memories.
Thank you, Chicago!
#ASCO25

[Prashant Chaulagain @Prashant_Med]

@vinibarzon Good luck Vini, Keep shining!!

[Prashant Chaulagain @Prashant_Med]

@RManochakian @MayoClinic @ReemaTawfiqMD @guicorreiamd @OsamaMosalemMD @MedWiest @sai_vaishnavi_k @NayefHikmat23 @TayoAdeoyeMD @A_Adel90 @DinaElantably @MayoCancerCare Congratulations Dr. @RManochakian , a true leader and mentor in the field.

[William Aird @WilliamAird4]

SUBSEGMENTAL PULMONARY EMBOLISM

... to anticoagulate or not to anticoagulate??

[Yüksel Ürün @DrYukselUrun]

BREAKING from @NEJM
In cancer patients w/ Cancer-Associated Venous Thromboembolism, reduced-dose apixaban (2.5 mg BID) is :
🔘Noninferior to full-dose (5 mg BID) for VTE recurrence
🔘Lower bleeding risk (12.1% vs. 15.6%)
🔘Safer extended anticoagulation, same protection.
#Thrombosis #cancer @OncoAlert @Cihan_Ay_MD
DOI: 10.1056/NEJMoa2416112

[Oncology Brothers @OncBrothers]

Durvalumab now @US_FDA approved in resectable MIBC based off #NIAGARA: Ph III, Gem/Cis +/- Durvalumab —> ✂️ —> post-op Durva

- New SoC
- 2 yr OS: 82.2% vs. 75.2% (HR: 0.75)
- 2yr EFS: 67.8% vs. 59.8% (HR: 0.68)
- Do we need adj Durva if pCR?

#OncTwitter #MedTwitter #gusm

[William Aird @WilliamAird4]

1/2

REMEMBER THE DOAC vs NOAC DEBATE?

The 1st oral anticoagulant, warfarin, was approved by the FDA in 1954.

In 2010, the FDA approved its first DOAC, dabigatran, followed by rivaroxaban (2011), apixaban (2012), in edoxaban (2015).